Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.

Silva RR, Skimming JW, Muniz R.

Clin Pediatr (Phila). 2010 Sep;49(9):840-51. doi: 10.1177/0009922810368289.

PMID:
20693523
2.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
3.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Stiefel G, Besag FM.

Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000. Review.

PMID:
20812768
4.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.

Awudu GA, Besag FM.

Drug Saf. 2014 Sep;37(9):661-76. doi: 10.1007/s40264-014-0201-8. Review.

PMID:
25124483
5.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

6.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
7.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
8.

Stimulants and sudden death: what is a physician to do?

Wilens TE, Prince JB, Spencer TJ, Biederman J.

Pediatrics. 2006 Sep;118(3):1215-9. Review.

PMID:
16951018
9.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
10.

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

Vitiello B.

Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):459-74, xi. doi: 10.1016/j.chc.2007.11.010. Review.

11.

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Epstein T, Patsopoulos NA, Weiser M.

Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD005041.

PMID:
25230710
12.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
13.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
14.

Management of a hyperactive teen and cardiac safety.

Sowinski H, Karpawich PP.

Pediatr Clin North Am. 2014 Feb;61(1):81-90. doi: 10.1016/j.pcl.2013.09.021. Epub 2013 Oct 30. Review.

PMID:
24267459
15.

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Antel J, Albayrak Ö, Heusch G, Banaschewski T, Hebebrand J.

Eur Arch Psychiatry Clin Neurosci. 2015 Apr;265(3):233-47. doi: 10.1007/s00406-014-0522-8. Epub 2014 Aug 23. Review.

PMID:
25149468
16.
17.

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R.

Can J Cardiol. 2009 Nov;25(11):625-30. Review.

18.
19.

Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.

Fredriksen M, Halmøy A, Faraone SV, Haavik J.

Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. Epub 2012 Aug 20. Review.

PMID:
22917983
20.

Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.

Hammerness PG, Surman CB, Chilton A.

Curr Psychiatry Rep. 2011 Oct;13(5):357-63. doi: 10.1007/s11920-011-0213-3. Review.

PMID:
21698412

Supplemental Content

Support Center